This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of fluticasone-salmeterol 115-21 12GM inhalers. The contract has a ceiling value of $3,304.98 and an ultimate completion date of November 29, 2024. This contract is not set aside and is part of the DLA's ECAT Generation V Program, a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that allows Dakota Drug, Inc. to deliver a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations.
Generated 3/2/25, 12:48 AM